Literature DB >> 27112094

Gout.

Nicola Dalbeth1, Tony R Merriman2, Lisa K Stamp3.   

Abstract

Gout is a chronic disease of deposition of monosodium urate crystals, which form in the presence of increased urate concentrations. Although environmental factors contribute to hyperuricaemia, renal and gut excretion of urate is central to regulation of serum urate, and genetic factors are important. Activation of the NLRP3 inflammasome and release of interleukin 1β have key roles in initiation of acute gout flares. A "treat to target serum urate" approach is essential for effective gout management; long-term lowering of serum urate to less than 360 μmol/L leads to crystal dissolution and ultimately to suppression of flares. An allopurinol dose-escalation strategy is frequently effective for achieving treatment targets, and several new urate-lowering drugs are also available. Worldwide, rates of initiation and continuation of urate-lowering therapy are very low, and, consequently, achievement of serum urate targets is infrequent. Strategies to improve quality of gout care are needed.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27112094     DOI: 10.1016/S0140-6736(16)00346-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  240 in total

1.  Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014.

Authors:  Franco Scinicariello; Melanie C Buser; Lina Balluz; Kimberly Gehle; H Edward Murray; Henry G Abadin; Roberta Attanasio
Journal:  Chemosphere       Date:  2020-06-20       Impact factor: 7.086

2.  Multimodal Enzyme Delivery and Therapy Enabled by Cell Membrane-Coated Metal-Organic Framework Nanoparticles.

Authors:  Jia Zhuang; Yaou Duan; Qiangzhe Zhang; Weiwei Gao; Shulin Li; Ronnie H Fang; Liangfang Zhang
Journal:  Nano Lett       Date:  2020-05-04       Impact factor: 11.189

3.  Atypical gouty mediastinal tophus mimicking thymoma on 18F-FDG PET/CT.

Authors:  Kevin Prigent; Bastien Jean-Jacques; Maxime Heyndrickx; Jean Jacques Michels; Nicolas Aide
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-15       Impact factor: 9.236

4.  Urate Bulla: a Rare Manifestation of Gout.

Authors:  Paul F Ehlers; Kip Mihara
Journal:  J Gen Intern Med       Date:  2019-03-18       Impact factor: 5.128

5.  β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares.

Authors:  Emily L Goldberg; Jennifer L Asher; Ryan D Molony; Albert C Shaw; Caroline J Zeiss; Chao Wang; Ludmilla A Morozova-Roche; Raimund I Herzog; Akiko Iwasaki; Vishwa Deep Dixit
Journal:  Cell Rep       Date:  2017-02-28       Impact factor: 9.423

Review 6.  Gout: Update on Dual-Energy Computed Tomography with Emphasis on Artifact Identification.

Authors:  Hillary W Garner; Daniel E Wessell
Journal:  Curr Rheumatol Rep       Date:  2018-11-13       Impact factor: 4.592

Review 7.  Lesinurad: A Review in Hyperuricaemia of Gout.

Authors:  Emma D Deeks
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

Review 8.  What Is the Evidence for Treat-to-Target Serum Urate in Gout?

Authors:  David Bursill; Nicola Dalbeth
Journal:  Curr Rheumatol Rep       Date:  2018-03-08       Impact factor: 4.592

9.  Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout - A cluster pattern analysis of dual-energy CT.

Authors:  Chio Yokose; Nicola Dalbeth; Jie Wei; Savvas Nicolaou; F Joseph Simeone; Scott Baumgartner; Maple Fung; Yuqing Zhang; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2019-07-11       Impact factor: 5.532

10.  Entheseal involvement of the lower extremities in gout: an ultrasonographic descriptive observational study.

Authors:  Guanhua Xu; Jin Lin; Junyu Liang; Yang Yang; Zi Ye; Guohui Zhu; Heng Cao
Journal:  Clin Rheumatol       Date:  2021-06-22       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.